CORONA Remedies Limited (NSE:CORONA)
| Market Cap | 136.80B |
| Revenue (ttm) | 15.59B +20.0% |
| Net Income | 2.07B +18.3% |
| EPS | 33.85 +18.3% |
| Shares Out | 61.16M |
| PE Ratio | 66.08 |
| Forward PE | 49.97 |
| Dividend | 10.00 (0.45%) |
| Ex-Dividend Date | Jun 19, 2026 |
| Volume | 25,615 |
| Open | 2,273.00 |
| Previous Close | 2,256.20 |
| Day's Range | 2,220.00 - 2,278.20 |
| 52-Week Range | 1,336.60 - 2,719.30 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 2,494.67 (+11.53%) |
| Earnings Date | Oct 30, 2026 |
About CORONA Remedies
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India. [Read more]
Financial Performance
In fiscal year 2026, CORONA Remedies's revenue was 14.03 billion, an increase of 17.28% compared to the previous year's 11.96 billion. Earnings were 1.85 billion, an increase of 23.88%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CORONA stock is "Strong Buy." The 12-month stock price target is ₹2,495, which is an increase of 11.53% from the latest price.
News
CORONA Remedies Transcript: Q2 26/27
Q2 revenue rose 22.2% YoY, led by 22.9% India growth and a chronic portfolio expanding ~29%. Guidance remains growth at 1.5x IPM, while investment in new therapies and hormone exports continues.
CORONA Remedies Slides: Q2 2027
CORONA Remedies has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 2, 2026.
CORONA Remedies Quarterly report: Q2 2027
CORONA Remedies has published its Q2 2027 quarterly earnings report on November 2, 2026.
CORONA Remedies Slides: Investor presentation
CORONA Remedies has posted slides in relation to its latest quarterly earnings report, which was published on October 29, 2026.
CORONA Remedies Transcript: Transcript
Q3 FY26 saw 15% YoY revenue growth and 24% YoY adjusted PAT growth, driven by strong chronic and semi-chronic therapy performance and strategic brand acquisitions. The company remains net cash positive, with robust return ratios and a stable outlook for mid-teen revenue and high-teen PAT growth.
CORONA Remedies Transcript: Transcript
Q1 FY 2027 saw 21.9% revenue growth and 30.1% PAT growth, driven by strong India business, robust volume and price gains, and leadership in chronic therapies. New hormone facility and brand expansion support long-term growth, with guidance maintained despite input cost risks.
CORONA Remedies Annual report
CORONA Remedies has published an annual report on August 24, 2026.
CORONA Remedies Transcript: Q2 25/26
Revenue and profit grew strongly in Q2 and H1 FY26, driven by chronic therapies and strategic acquisitions. Guidance targets 15% CAGR revenue and 20% PAT/EPS growth, with new launches and international expansion planned. ROE and ROCE remain robust.
CORONA Remedies Quarterly report: Q2 2026
CORONA Remedies has published its Q2 2026 quarterly earnings report on January 5, 2026.
CORONA Remedies Slides: Q2 2026
CORONA Remedies has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 5, 2026.